Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator

Background— Whether sex differences in implantable cardioverter-defibrillator (ICD) benefit exist remains unanswered. We evaluated sex differences in mode of death among a large cohort of ambulatory heart failure patients who meet criteria for a primary prevention ICD. Methods and Results— Patients from 5 trials or registries were included if they met American College of Cardiology/American Heart Association/Heart Rhythm Society guideline criteria for implantation of a primary prevention ICD. We investigated the potential sex differences in total deaths and total deaths by mode of death. The relationship between the estimated total mortality and mode of death by percentage of total mortality was also analyzed by sex. The Seattle Heart Failure Model was used to estimate total mortality in this analysis. A total of 8337 patients (1685 [20%] women) met inclusion criteria. One-year mortality was 10.8±0.3%. In women, the age-adjusted all-cause mortality was 24% lower (hazard ratio [HR], 0.76; confidence interval [CI], 0.68–0.85; P<0.0001), the risk of sudden death was 31% lower (HR, 0.69; CI, 0.58–0.83; P<0.0001), but no significant difference in pump failure death was observed. Throughout a range of total mortality risk, women had a 20% lower all-cause mortality (HR, 0.80; CI, 0.71–0.89; P<0.001) and 29% fewer deaths that were sudden (HR, 0.71; CI, 0.59–0.86;P<0.001) compared with men. Conclusions— Women with heart failure have a lower mortality than men, and fewer of those deaths are sudden throughout a spectrum of all-cause mortality risk. These data provide a plausible reason for and thus support the possibility that sex differences in ICD benefit may exist.

[1]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[2]  S. Solomon,et al.  Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. , 2011, Journal of the American College of Cardiology.

[3]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[4]  A. Natale,et al.  Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. , 2010, Heart rhythm.

[5]  James A. Ker,et al.  Heart failure : review , 2010 .

[6]  H. Ghanbari,et al.  Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.

[7]  D. Mozaffarian,et al.  Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.

[8]  A. Laupacis,et al.  Design and implementation of a population-based registry of Implantable Cardioverter Defibrillators (ICDs) in Ontario. , 2008, Heart rhythm.

[9]  J. Ornato,et al.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.

[10]  Mark A Hlatky,et al.  ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. , 2008, Heart rhythm.

[11]  L. Lund,et al.  Abstract 2308: Does Peak Oxygen Consumption add to the Seattle Heart Failure Model? , 2007 .

[12]  D. Mozaffarian,et al.  Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. , 2007, The American journal of cardiology.

[13]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[14]  M. Haigney,et al.  Gender Differences in Na/Ca Exchanger Current and β‐Adrenergic Responsiveness in Heart Failure in Pig Myocytes , 2007, Annals of the New York Academy of Sciences.

[15]  C. White,et al.  The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death , 2006, Journal of internal medicine.

[16]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[17]  S. Connolly,et al.  Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. , 2005, European heart journal.

[18]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[19]  L. Tavazzi,et al.  Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. , 2005, Journal of cardiac failure.

[20]  T. Saikawa,et al.  Gender Differences in Autonomic Modulation of Ventricular Repolarization in Humans , 2005, Journal of cardiovascular electrophysiology.

[21]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[22]  J. Spertus,et al.  Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. , 2004, The American journal of cardiology.

[23]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[24]  W. Kannel,et al.  Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.

[25]  A. Kadish,et al.  DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.

[26]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[27]  N. Hollenberg,et al.  Literature alert , 2002 .

[28]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[29]  G. Helguera,et al.  Remodeling of Kv4.3 Potassium Channel Gene Expression under the Control of Sex Hormones* , 2001, The Journal of Biological Chemistry.

[30]  Andrew N. Carr,et al.  Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium. , 2001, Journal of molecular and cellular cardiology.

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.